Second-generation antipsychotic medications and risk of pneumonia in schizophrenia

Schizophrenia Bulletin

Volumn 39, Issue 3, 2013, Pages 648-657

  Kuo, Chian Jue ^a,b,c   Yang, Shu Yu ^a,d   Liao, Ya Tang ^b   Chen, Wei J ^b   Lee, Wen Chung ^b   Shau, Wen Yi ^e   Chang, Yao Tung ^a   Tsai, Shang Ying ^c   Chen, Chiao Chicy ^a,c  

^a TAIPEI CITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e Center for Drug Evaluation   (Taiwan)

Author keywords

clozapine; dose dependent; pneumonia; second generation antipsychotics

Indexed keywords

AMISULPRIDE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZOTEPINE;

ADULT; AGED; ARTICLE; ASTHMA; BRONCHOPNEUMONIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; DELIRIUM; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; FEMALE; HEALTH STATUS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INCIDENCE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PNEUMONIA; POLYPHARMACY; PRIORITY JOURNAL; SCHIZOPHRENIA; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CASE-CONTROL STUDIES; CLOZAPINE; COHORT STUDIES; DIBENZOTHIAZEPINES; DIBENZOTHIEPINS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PNEUMONIA; RISK FACTORS; RISPERIDONE; SCHIZOPHRENIA; SULPIRIDE; TAIWAN;

EID: 84876533595     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbr202     Document Type: Article

References (40)

1. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory metaanalysis of randomized, controlled trials. Am J Psychiatry. 2003;160:1209-1222. (Pubitemid 41070936)
2. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003;361:1581-1589. (Pubitemid 36578993)
3. Awad AG, Voruganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs. 2004;18:877-893. (Pubitemid 39612017)
4. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223. (Pubitemid 41345943)
5. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63:1079-1087. (Pubitemid 44498387)
6. Bai YM, Lin CC, Chen JY, Chen TT, Su TP, Chou P. Association of weight gain and metabolic syndrome in patients taking clozapine: an 8-year cohort study. J Clin Psychiatry. 2011;72:751-756.
7. Remington G. Schizophrenia, antipsychotics, and the metabolic syndrome: is there a silver lining? Am J Psychiatry. 2006;163:1132-1134. (Pubitemid 44464436)
8. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64:1123-1131. (Pubitemid 47529346)
9. Knol W, van Marum RJ, Jansen PA, Souverein PC, Schobben AF, Egberts AC. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc. 2008;56:661-666. (Pubitemid 351473519)
10. Trifiro G, Gambassi G, Sen EF, et al. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-control study. Ann Intern Med. 2010;152:418-425, W139-440.
11. U.S. Food and Drug Administration, ed. Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioural Disturbances. Silver Spring, MD: U.S. Food and Drug Administration; 2005. http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsand Providers/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053171. htm.
12. U.S. Food and Drug Administration, ed. FDA Requests Boxed Warnings on Older Class of Antipsychotic Drugs. Silver Spring, MD: U.S. Food and Drug Administration; 2008. http://www.fda.gov/NewsEvents/Newsroom/Press Announcements/2008/ucm116912.htm.
13. Barnett MJ, Perry PJ, Alexander B, Kaboli PJ. Risk of mortality associated with antipsychotic and other neuropsychiatric drugs in pneumonia patients. J Clin Psychopharmacol. 2006;26:182-187. (Pubitemid 43740344)
14. Yang SY, Kao Yang YH, Chong MY, Yang YH, Chang WH, Lai CS. Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study. Clin Pharmacol Ther. 2007;81:586-594.
15. Trifiro G. Antipsychotic drug use and community-acquired pneumonia. Curr Infect Dis Rep. 2011;13:262-268.
16. McElroy SL, Nelson EB, Welge JA, Kaehler L, Keck PE Jr. Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial. J Clin Psychiatry. 2008;69:433-440. (Pubitemid 351549397)
17. Cordes J, Streit M, Loeffler S, von Wilmsdorff M, Agelink M, Klimke A. Reversible neutropenia during treatment with olanzapine: three case reports. World J Biol Psychiatry. 2004;5:230-234. (Pubitemid 44121703)
18. Taylor DM, Douglas-Hall P, Olofinjana B, Whiskey E, Thomas A. Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection. Br J Psychiatry. 2009;194:165-167.
19. Chen YH, Lin HC. Poor Clinical Outcomes Among Pneumonia Patients With Schizophrenia. Schizophr Bull. 2011;37: 1088-1194.
20. Weissman JS, Gatsonis C, Epstein AM. Rates of avoidable hospitalization by insurance status in Massachusetts and Maryland. JAMA. 1992;268:2388-2394.
21. Wu CS, Wang SC, Cheng YC, Gau SS. Association of cerebrovascular events with antidepressant use: a case-crossover study. Am J Psychiatry. 2011;168:511-521.
22. Gau SS, Chao PF, Lin YJ, Chang CJ, Gau CS. The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: a nested matched case-control study. J Clin Psychopharmacol. 2008;28:509-517.
23. Gau CS, Chang CJ, Tsai FJ, Chao PF, Gau SS. Association between mood stabilizers and hypothyroidism in patients with bipolar disorders: a nested, matched case-control study. Bipolar Disord. 2010;12:253-263.
24. Gau SS, Chung CH, Gau CS. A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in Taiwan. J Clin Psychopharmacol. 2008;28:271-278.
25. WHO Collaborating Centre for Drug Statistic Methodology. ATC index with DDDs.Oslo, Norway: WHO; 2009.
26. Mantel-Teeuwisse AK, Klungel OH, Verschuren WM, Porsius A, de Boer A. Comparison of different methods to estimate prevalence of drug use by using pharmacy records. J Clin Epidemiol. 2001;54:1181-1186. (Pubitemid 33033249)
27. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130-1139. (Pubitemid 41587600)
28. Quail JM, Lix LM, Osman BA, Teare GF. Comparing comorbidity measures for predicting mortality and hospitalization in three population-based cohorts. BMC Health Serv Res. 2011;11:146.
29. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;79:516-524.
30. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epidemiol. 2006;163:1149-1156. (Pubitemid 43987579)
31. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med. 1993;329:162-167. (Pubitemid 23195736)
32. Nielsen J, Foldager L, Meyer JM. Increased use of antibiotics in patients treated with clozapine. Eur Neuropsychopharmacol. 2009;19:483-486.
33. Maddalena AS, Fox M, Hofmann M, Hock C. Esophageal dysfunction on psychotropic medication. A case report and literature review. Pharmacopsychiatry. 2004;37:134-138. (Pubitemid 38680336)
34. Hinkes R, Quesada TV, Currier MB, Gonzalez-Blanco M. Aspiration pneumonia possibly secondary to clozapineinduced sialorrhea. J Clin Psychopharmacol. 1996;16:462-463. (Pubitemid 26423315)
35. Fauci AS, Braunwald E, Kasper DL, et al. Harrison's Principles of Internal Medicine. 17th ed. New York, NY: McGraw-Hill Professional; 2008.
36. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
37. Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry. 2010;71:1115-1124.
38. Boyer P, Lecrubier Y, Stalla-Bourdillon A, Fleurot O. Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiology. 1999;39:25-32. (Pubitemid 29037761)
39. Smeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study. J Affect Disord. 1998;48: 47-56. (Pubitemid 28078970)
40. Almirall J, Gonzalez CA, Balanzo X, Bolibar I. Proportion of community-acquired pneumonia cases attributable to tobacco smoking. Chest. 1999;116:375-379. (Pubitemid 29382121)